Xenon Pharmaceuticals is a clinical-stage biopharma focused on neurology and ion-channel biology. Its lead program, azetukalner (XEN1101), is an oral potassium-channel modulator in late-stage development for epilepsy and other neurological indications. The company builds a pipeline of precision neuroscience candidates aimed at disorders with significant unmet need rather than commercial primary-care products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 7.5 | — | -65 | — |
| Q2 2025 | 0 | — | -84.7 | — |
| Q3 2025 | 0 | — | -90.9 | — |
| Q4 2025 | 0 | — | -105.3 | — |
| Q1 2026 | 0 | -100% | -102.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: PTC Therapeutics, Inc. (PTCT), ExlService Holdings, Inc. (EXLS), Crocs, Inc. (CROX), Red Rock Resorts, Inc. (RRR), MarketAxess Holdings Inc. (MKTX), Versant Media Group, Inc. (VSNT)